We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC

Delisted

SGMO was delisted on the 4th of May, 2026.

217 hedge funds and large institutions have $1.1B invested in SANGAMO THERAPEUTICS INC in 2018 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 74 increasing their positions, 57 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 57

25% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 28

19% more capital invested

Capital invested by funds: $919M → $1.1B (+$178M)

3% more funds holding

Funds holding: 210217 (+7)

0% more call options, than puts

Call options by funds: $36.1M | Put options by funds: $36M

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.09% less ownership

Funds ownership: 63.79%63.7% (-0.09%)

Holders
217
Holders Change
+7
Holders Change %
+3.33%
% of All Funds
4.96%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
35
Increased
74
Reduced
57
Closed
28
Calls
$36.1M
Puts
$36M
Net Calls
+$97K
Net Calls Change
+$2.61M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$141M +$3.64M +239,190 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$127M -$10.4M -686,132 -8%
State Street
3
State Street
Massachusetts
$110M +$6.57M +431,983 +7%
WA
4
Wasatch Advisors
Utah
$77M +$7.39M +486,429 +12%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$45M -$10.1M -662,945 -20%
CS
6
Credit Suisse
Switzerland
$37M +$6.32M +415,764 +24%
CC
7
Casdin Capital
New York
$33.9M +$9.12M +600,000 +43%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$23.7M -$28.1M -1,850,000 -57%
Northern Trust
9
Northern Trust
Illinois
$22.4M +$534K +35,166 +3%
BBA
10
Baker Bros. Advisors
New York
$21.8M
RPAM
11
Rhenman & Partners Asset Management
Sweden
$20.3M +$2.21M +145,424 +14%
Wellington Management Group
12
Wellington Management Group
Massachusetts
$19.8M +$15.5M +1,016,644 +666%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$18.9M +$487K +32,047 +3%
Goldman Sachs
14
Goldman Sachs
New York
$18.8M +$9.13M +600,719 +118%
TA
15
Teachers Advisors
New York
$17M +$1.11M +73,264 +8%
Deutsche Bank
16
Deutsche Bank
Germany
$15.5M +$2.13M +139,899 +18%
AC
17
Alexandria Capital
Virginia
$15.2M -$26.6K -1,753 -0.2%
Wells Fargo
18
Wells Fargo
California
$15.1M +$1.52M +100,253 +13%
TAM
19
Tocqueville Asset Management
New York
$12.1M +$5.63M +370,297 +109%
UBS AM
20
UBS AM
Illinois
$11.5M -$657K -43,203 -6%
PCM
21
Peregrine Capital Management
Minnesota
$10.4M +$67.3K +4,430 +0.7%
Morgan Stanley
22
Morgan Stanley
New York
$10M -$4.9M -322,390 -35%
Charles Schwab
23
Charles Schwab
California
$9.99M +$360K +23,698 +4%
TCIM
24
TIAA CREF Investment Management
New York
$9.46M +$692K +45,520 +9%
Handelsbanken Fonder
25
Handelsbanken Fonder
Sweden
$9.24M +$2.86M +188,000 +53%

SGMO Hedge Fund Activity: Q3 2018 in Review

217 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2018, worth a combined $1.1B — up 19% from $919M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new SGMO positions and 28 closed out — a net gain of 7 holders — while 74 added to existing stakes and 57 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $15.5M. The largest seller was Adage Capital Partners, cutting an estimated $28.1M.

  • 217 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2018, up from 210 in Q2 2018.
  • Funds reported $1.1B of SANGAMO THERAPEUTICS INC stock for Q3 2018, up 19% quarter-over-quarter.
  • 35 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2018 and 28 closed out, a net change of +7 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q3 2018 was Wellington Management Group, an estimated $15.5M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q3 2018 was Adage Capital Partners, an estimated $28.1M sold.

Based on aggregated 13F filings for Q3 2018.